[HTML][HTML] Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

N Albinger, J Hartmann, E Ullrich - Gene therapy, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …

Driving CAR T-cells forward

HJ Jackson, S Rafiq, RJ Brentjens - Nature reviews Clinical oncology, 2016 - nature.com
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

[PDF][PDF] Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta

A Griciuc, A Serrano-Pozo, AR Parrado, AN Lesinski… - Neuron, 2013 - cell.com
The transmembrane protein CD33 is a sialic acid-binding immunoglobulin-like lectin that
regulates innate immunity but has no known functions in the brain. We have previously …

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

SS Kenderian, M Ruella, O Shestova, M Klichinsky… - Leukemia, 2015 - nature.com
Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis.
Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ …

[HTML][HTML] Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

A Ehninger, M Kramer, C Röllig, C Thiede… - Blood cancer …, 2014 - nature.com
Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …

[HTML][HTML] Neutrophils: need for standardized nomenclature

E McKenna, AU Mhaonaigh, R Wubben… - Frontiers in …, 2021 - frontiersin.org
Neutrophils are the most abundant innate immune cell with critical anti-microbial functions.
Since the discovery of granulocytes at the end of the nineteenth century, the cells have been …

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9

R Beatson, V Tajadura-Ortega, D Achkova, G Picco… - Nature …, 2016 - nature.com
Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant
glycosylation occurs in essentially all types of cancers and results in increased sialylation …

Ocular adverse events associated with antibody–drug conjugates in human clinical trials

JS Eaton, PE Miller, MJ Mannis… - Journal of Ocular …, 2015 - liebertpub.com
This article reviews ocular adverse events (AEs) reported in association with administration
of antibody–drug conjugates (ADCs) in human clinical trials. References reporting ocular …

[HTML][HTML] Radiolabeled antibodies for cancer imaging and therapy

S Parakh, ST Lee, HK Gan, AM Scott - Cancers, 2022 - mdpi.com
Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …

[HTML][HTML] The expansion of targetable biomarkers for CAR T cell therapy

MH Townsend, G Shrestha, RA Robison… - Journal of Experimental & …, 2018 - Springer
Biomarkers are an integral part of cancer management due to their use in risk assessment,
screening, differential diagnosis, prognosis, prediction of response to treatment, and …